"It is estimated that the GLP-1 market will exceed $100 bn by 2030, driven equally by diabetes and obesity usage. In the US alone, total GLP-1 users may be as much as 30 million by 2030 - that's around 9 per cent of the overall population (1). Here at Stevanato Group we believe that today, and for the foreseeable future, auto-injectors and pen injectors will remain at the fulcrum of GLP-1 delivery. And whilst this potential blockbuster treatment presents considerable opportunities for pharma partners, there are of course challenges, specifically in terms of satisfying demand.
In this article we will review the growth in demand for GLP-1 treatments and present Stevanato Group's response to this exciting opportunity, showcasing its Alina device platform for pen injectors and the Aidaptus two-step, single-use auto-injector.
In 1986, ten years after it was first introduced by Smith Kline & French, sales of peptic ulcer treatment Tagamet surpassed the $1 billion mark, making it the first drug in history to be classified as a blockbuster (2).
Since then, the pharmaceutical industry has welcomed a host of therapies and vaccines into this revered club, with indications covering everything from cancer and COVID-19 to arthritis and atrial fibrillation. In recent times, however, much of the attention in the blockbuster category has been focused on glucagon-like peptide-1 receptor agonists (GLP-1 agonists). These drugs were originally established as treatments for managing blood-sugar levels in people with Type 2 diabetes but have experienced a recent dramatic boom in demand as treatments for obesity.
This story is from the December 2024 edition of Express Pharma.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.
Already a subscriber ? Sign In
This story is from the December 2024 edition of Express Pharma.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.
Already a subscriber? Sign In
Blissfill-Calibrated syringe pipettes for repetitive laboratory dosing as per ISO 8655-9
Blissfill syringe pipettes provide laboratories with an ergonomic, self-refilling solution for repetitive dosing, delivering precise volumes from 0.05ml to 10ml. With ISO 8655-9 compliance and an included calibration certificate, Blissfill ensures accuracy and ease of use for high-demand lab applications
Ensuring pharma compliance with testo data measurement technology
Comprehensive data measurement tools address regulatory demands and secure quality in pharma
Waters launches software for lab-centric business intelligence enabling audit readiness
waters_connect Data Intelligence software provides laboratories with comprehensive business intelligence on their chromatographic data throughout the product development lifecycle, enabling real-time audit readiness and query response, while reducing time spent on audit preparation
Ensuring clean room integrity with Prime Clean Reset High-Speed Doors
Designed with precision to meet the stringent requirements of controlled environments, Prime Clean Reset is the epitome of performance and reliability, ensuring that your clean room operations consistently meet the highest standards of regulatory compliance and product integrity
Optimising efficiency with Remote Laboratory Solutions
LabWare's comprehensive suite of software solutions designed specifically for laboratories offers reliable Remote Laboratory Solutions to help your business thrive in the current climate
Ensuring water quality with the 6000TOCi: The ultimate solution for continuous TOC measurement
The 6000TOCi Sensor is a comprehensive solution that brings together continuous monitoring, rapid response, reliability, and compliance
Enhancing pharmaceutical analysis in critical areas
Dheeraj Handique, Manager GC/GCMS Product Marketing, Shimadzu Analytical (India) highlights the benefits of GCMS-TQ8050 NX with HS-20 NX trap for genotoxic impurities, nitrosamines, and, extractables and leachables
Technical innovations for Annex 1
To meet the stringent EU GMP Annex 1 requirements, Optima presents innovative solutions to improve product and patient safety in pharmaceutical manufacturing. From minimising glove interventions and optimising First Air flow to advanced automation for integrity testing, this article explores how Optima's technologies support compliance in aseptic fill-and-finish processes
JRS Pharma - The Global MCC Manufacturing Network
JRS Pharma is one of the largest manufacturers of MCC across the globe. The know-how is based on more than 25 years of experience in development of own processes
Mack Pharmatech is the first to launch PLC-based environmental chambers in India
Manoj Choudhari, Managing Director, Mack Pharmatech shares insights on his company's pioneering expand globally and enhance regulatory compliance